Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning

How does Novo Nordisk Wegovy stack up against Lilly?

At the American Diabetes Association’s Scientific Sessions in New Orleans, Novo Nordisk CEO Mike Doustdar confirmed Wegovy prescriptions have exceeded 3 million in just five months — a pace that outpaces Eli Lilly’s Foundayo, whose prescription count remains undisclosed but was described by Lilly CEO Dave Ricks as ‘markedly higher’ than the 20,000 reported six weeks ago. While Foundayo benefits from simpler dosing — no fasting required — Wegovy’s label includes FDA-approved cardiovascular and renal risk reduction, a key differentiator for seniors entering Medicare’s new $50 co-pay program. Citigroup analysts noted that ‘Wegovy’s multi-organ protection profile remains unmatched in the oral GLP-1 class,’ though they maintain a ‘Neutral’ rating with a $45.00 price target.

What does Medicare’s $50 program mean for Wall Street?

Starting July 1, 2026, Medicare Part D beneficiaries will access Wegovy and Foundayo for just $50 per month — a seismic shift from prior out-of-pocket costs exceeding $1,300 monthly. For U.S. investors, this unlocks a 64-million-patient addressable market overnight. Novo Nordisk is preparing aggressive direct-to-consumer campaigns emphasizing Wegovy’s heart and kidney benefits, while Lilly leans into convenience. Morgan Stanley analysts estimate Medicare adoption could lift Wegovy’s U.S. sales by 35% in H2 2026 — but only if supply constraints ease. The company’s $450 million U.S. manufacturing expansion in North Carolina is now on accelerated timeline, with first commercial batches expected by August.

Why did NVO drop 4.5% despite the Wegovy milestone?

Wall Street reacted negatively to Eli Lilly’s retatrutide Phase 3 data — showing 19% average weight loss and just 4% discontinuation due to side effects — juxtaposed with Novo Nordisk’s lack of near-term pipeline catalysts. Zealand Pharma’s Servodutide failure (19% dropout rate due to nausea/vomiting) helped Lilly and Novo Nordisk, yet investors punished NVO for its slower progress on triple-agonist development. Barclays analysts wrote: ‘While Wegovy’s commercial execution is elite, the absence of a retatrutide-equivalent in Novo’s near-term pipeline remains a valuation headwind.’ The stock’s 52-week low sits at $23.15 — meaning current levels still imply significant downside risk relative to peak sentiment.

What’s next for Novo Nordisk’s EU and U.S. expansion?

Regulatory tailwinds are mounting outside the U.S.: The European Medicines Agency’s CHMP granted positive opinions for both the oral Wegovy pill and the high-dose 7.2 mg single-dose pen — expected to launch in Q3 2026. The latter achieved over 20% mean weight loss in trials and could reassert Novo Nordisk’s leadership in Europe, where it still commands ~65% GLP-1 market share. Meanwhile, the company’s DKK 15 billion share buyback is 28% complete, with DKK 4.17 billion deployed by mid-May. TipRanks’ AI Analyst Spark maintains an ‘Outperform’ rating, citing ‘strong profitability and attractive valuation’ despite near-term pipeline concerns. The company’s Parkinson’s therapy handoff to Boston-based Cellular Intelligence — backed by Mark Zuckerberg — signals strategic diversification beyond obesity, though near-term Wall Street focus remains squarely on Novo Nordisk Wegovy execution.

Related Coverage: Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1 combination wave? With NVIDIA’s AI tools accelerating clinical trial analysis and Tesla’s battery tech enabling next-gen cold-chain logistics for GLP-1 biologics, biotech infrastructure plays are gaining traction among S&P 500 investors. Meanwhile, Apple’s rumored health-integration roadmap could reshape patient adherence tracking — a key metric for payers evaluating long-term GLP-1 cost-effectiveness.

Novo Nordisk Wegovy remains the most prescribed GLP-1 pill in the U.S. — and its 3 million prescriptions prove commercial resilience amid fierce competition. For U.S. portfolios, the stock’s current valuation offers asymmetric upside if Medicare adoption exceeds expectations and the high-dose pen gains traction in Europe. The next catalyst arrives in late July, when Novo Nordisk reports Q2 2026 earnings and provides updated guidance on Wegovy’s share of the $50 Medicare program.